MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges
A Mansouri, LD Hachem, S Mansouri, F Nassiri… - Neuro …, 2019 - academic.oup.com
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally
poor prognosis. The emergence of molecular biomarkers has had a significant impact on …
poor prognosis. The emergence of molecular biomarkers has had a significant impact on …
Tumor heterogeneity in glioblastomas: from light microscopy to molecular pathology
Simple Summary Glioblastomas (GBMs) are the most frequent and aggressive malignant
tumors arising in the human brain. One of the main reasons for GBM aggressiveness is its …
tumors arising in the human brain. One of the main reasons for GBM aggressiveness is its …
MGMT status as a clinical biomarker in glioblastoma
Glioblastoma is the most common primary malignant brain tumor. Although current standard
therapy extends median survival to~ 15 months, most patients do not have a sustained …
therapy extends median survival to~ 15 months, most patients do not have a sustained …
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a …
Background The DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT)
causes resistance of tumor cells to alkylating agents. It is a predictive biomarker in high …
causes resistance of tumor cells to alkylating agents. It is a predictive biomarker in high …
Integrating artificial intelligence and machine learning into cancer clinical trials
J Kang, AK Chowdhry, SL Pugh, JH Park - Seminars in Radiation Oncology, 2023 - Elsevier
The practice of oncology requires analyzing and synthesizing abundant data. From the
patient's workup to determine eligibility to the therapies received to the post-treatment …
patient's workup to determine eligibility to the therapies received to the post-treatment …
[HTML][HTML] Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials
F Lieberman - F1000Research, 2017 - ncbi.nlm.nih.gov
This is an exciting time in neuro-oncology. Discoveries elucidating the molecular
mechanisms of oncogenesis and the molecular subtypes of glioblastoma multiforme (GBM) …
mechanisms of oncogenesis and the molecular subtypes of glioblastoma multiforme (GBM) …
The prognostic value of preoperative systemic inflammatory response index (SIRI) in patients with high-grade glioma and the establishment of a nomogram
Q He, L Li, Q Ren - Frontiers in Oncology, 2021 - frontiersin.org
Background The predictive value of systemic inflammatory response index (SIRI) was
confirmed in some malignant tumors. However, few studies investigated the prognostic …
confirmed in some malignant tumors. However, few studies investigated the prognostic …
Clinically relevant imaging features for MGMT promoter methylation in multiple glioblastoma studies: a systematic review and meta-analysis
CH Suh, HS Kim, SC Jung… - American Journal of …, 2018 - Am Soc Neuroradiology
BACKGROUND: O6-methylguanine methyltransferase (MGMT) promoter methylation status
has been reported as a prognostic biomarker in clinical trials. PURPOSE: Our aim was to …
has been reported as a prognostic biomarker in clinical trials. PURPOSE: Our aim was to …
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma
L Lazaridis, N Schäfer, S Teuber-Hanselmann… - Journal of cancer …, 2020 - Springer
Purpose In the EF-14 trial for newly diagnosed glioblastoma (ndGBM) patients addition of
Tumour Treating Fields (TTFields) to temozolomide treatment resulted in a significantly …
Tumour Treating Fields (TTFields) to temozolomide treatment resulted in a significantly …
Personalized risk prediction in clinical oncology research: applications and practical issues using survival trees and random forests
C Hu, JA Steingrimsson - Journal of biopharmaceutical statistics, 2018 - Taylor & Francis
ABSTRACT A crucial component of making individualized treatment decisions is to
accurately predict each patient's disease risk. In clinical oncology, disease risks are often …
accurately predict each patient's disease risk. In clinical oncology, disease risks are often …